Morgan Stanley lifts Vertex stock price target to $459

On Tuesday, Morgan Stanley (NYSE:MS) adjusted its outlook on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares, raising the price target from the previous $450.00 to $459.00, while maintaining an Equalweight rating on the stock. Currently trading at $469.97 with a market capitalization of $121 billion, InvestingPro analysis suggests the stock is slightly overvalued at current levels. The revision follows Vertex’s recent financial performance and guidance update.

Vertex reported a stronger-than-expected performance for the fourth quarter, surpassing analyst predictions. With revenue growth of 10% and an overall "GOOD" financial health rating according to InvestingPro, the company has demonstrated solid operational execution. The company also provided its first revenue and expense guidance for the year 2025, which aligned with the consensus estimates. This financial update has prompted Morgan Stanley to revise its price target upwards.

The attention of investors and analysts is now turning towards the upcoming product launches of Journavx and Alyftrek. These new treatments are anticipated to be significant for Vertex’s growth and market position.

Morgan Stanley’s updated price target of $459 reflects the firm’s new estimates based on Vertex’s current trajectory and future prospects. This adjustment indicates a nuanced view of the company’s valuation, factoring in the latest developments and expected performance.

Vertex’s stock performance in the upcoming period is likely to be influenced by the market’s reception of Journavx and Alyftrek, as well as the company’s ability to meet the financial targets set for 2025. The Equalweight rating suggests that Morgan Stanley views the company’s stock as fairly valued at the current level, relative to its peers.

In other recent news, Vertex Pharmaceuticals Incorporated has been the focus of several analyst reports and financial updates. Scotiabank (TSX:BNS) raised Vertex’s stock price target to $450, following a strong fourth-quarter performance in 2024, with total revenues surpassing consensus by $131 million, reaching $2.91 billion. However, the company’s non-GAAP earnings per share (EPS) for the fourth quarter were slightly below expectations at $3.98, missing by $0.07.

Piper Sandler maintained an Overweight rating and a $533.00 price target on Vertex’s stock, expressing confidence in the company’s robust pipeline of developmental treatments and growing financial resources. Cantor Fitzgerald also reaffirmed its Overweight rating on Vertex with a consistent price target of $480.00, focusing on the potential effects of its medication Alyftrek on the company’s margins and earnings per share (EPS).

Bernstein SocGen Group adjusted its price target for Vertex, increasing it slightly from $441.00 to $444.00 while maintaining a Market Perform rating. The company reported $2.9 billion in revenue, surpassing estimates by 5%. Vertex’s management expressed optimism about the recent launches of their drugs Journavx and Alyftrek, anticipated to be significant growth drivers for Vertex’s stock throughout 2025.

These are the recent developments for Vertex, which reported fourth-quarter revenue that exceeded analyst estimates and provided strong full-year 2025 guidance, signaling continued growth expectations. The company posted revenue of $2.91 billion, surpassing the consensus estimate of $2.79 billion, representing a 16% increase compared to the same quarter last year, primarily driven by the strong performance of its cystic fibrosis drug TRIKAFTA/KAFTRIO.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.